Half-year report · Q2
4544.TEDINET S100UPH6
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥120.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥236.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥116.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥956m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥7.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | −¥1.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥291.4bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥290.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥284.6bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥155.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥148.3bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥136.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥142.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥150.1bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥47.0bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥39.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥47.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥37.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥16.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-14.47 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-132.77 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-32 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 46.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥2.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥76.7bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥76.5bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥205m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2.9bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥31.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥29.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥14.5bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥14.4bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥879m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥122.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥120.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥3.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥2.8bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥72.4bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥72.3bn |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥74m |
| jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥6.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥33.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.2bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.0bn |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3m |
| jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥564m |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥119.6bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥116.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 536
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 119987000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 205000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 2214000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 9000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 2428000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -2428000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 76723000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 31234000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 14457000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 122415000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -2428000000 | JPY |
| Net sales | CurrentYTDDuration | 119987000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | -2892000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 5481000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 879000000 | JPY |
| Operating income | CurrentYTDDuration_ReportableSegmentsMember | 3468000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -2511000000 | JPY |
| Operating income | CurrentYTDDuration | 956000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第75期中（自 2024年４月１日 至 2024年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)H.U.グループホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | H.U. Group Holdings, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)取締役 代表執行役会長 兼 社長 兼 グループCEO 竹内 成和 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区赤坂一丁目８番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)０３（６２７９）０８０１（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 執行役常務 兼 CFO 北村 直樹 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区赤坂一丁目８番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０３（６２７９）０９２６ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 執行役常務 兼 CFO 北村 直樹 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00967 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45440 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)H.U.グループホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | H.U. Group Holdings, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |